Business
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:
About this update from Biomerica, Inc.
[{"type":"image","alt":"Biomerica, Inc.","displaySize":"","headline":null,"caption":"Biomerica, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":232,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m66J9gaNGHXIlBdKngBmxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca","width":232,"height":39}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS.","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":425,"olType":false},{"type":"text","content":"IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's inFoods® IBS test, establishing a national Medicare payment rate of $300 under the Clinical Laboratory Fee Schedule (CLFS). The pricing will apply to claims for InFoods IBS tests that Medicare approves and pays with dates of service on or after January 1, 2026.","length":536,"tagName":"p"},{"type":"text","content":"This milestone follows the American Medical Association's (AMA) approval of a unique CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, which became effective October 1, 2025. The CMS pricing determination establishes a clear national payment rate for the test and this pricing clarity should expand patient access.","length":334,"tagName":"p"},{"type":"text","content":"Significant Commercial Milestone","length":32,"tagName":"p"},{"type":"text","content":"The $300 CLFS payment rate provides a foundation for negotiations wit...